Waldenström macroglobulinemia: My way

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 464-471

  Gertz, Morie ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Macroglobulinemia; Prognosis; Waldenstr m

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN M; LENALIDOMIDE; M PROTEIN; OFATUMUMAB; POMALIDOMIDE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE;

DISEASE CLASSIFICATION; DRUG EFFICACY; EVENT FREE SURVIVAL; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; PYRAZINES; SURVIVAL ANALYSIS; THALIDOMIDE; WALDENSTROM MACROGLOBULINEMIA;

EID: 84873366428     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.717173     Document Type: Review

References (62)

1. Kyle RA, Dispenzieri A, Kumar S, et al. IgM monoclonal gammopathy of undetermined signif cance (MGUS) and smoldering Waldenstrom's macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk 2011;11: 74-76.
2. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined signif cance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85: 945-948.
3. Landgren O, Kyle RA, Rajkumar SV. Frommyelomaprecursordisease to multiple myeloma: new diagnostic concepts and opportunities for earlyintervention. Clin Cancer Res 2011;17: 1243-1252.
4. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined signif cance and smoldering Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9: 17-18.
5. Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012;118: 3793-3800.
6. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined signif cance and multiple myeloma between blacks and whites. Leukemia 2012;26: 609-614.
7. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined signif cance among men in Ghana. Mayo Clin Proc 2007;82: 1468-1473.
8. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30: 110-115.
9. Iida S, Rao PH, Ueda R, et al. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma 1999: 34: 25-33.
10. Ackroyd S, O'Connor SJ, Owen RG. Rarity of IgH translocations in Waldenstrom macroglobulinemia. Cancer Genet Cytogenet 2005;163: 77-80.
11. Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol 2007;47: 31-42.
12. Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin Diagn Pathol 2011: 28: 245-255.
13. Panayiotidis P, Kotsi P. Genetics of small lymphocyte disorders. Semin Hematol 1999;36: 171-177.
14. Janssens A, Van Roy N, Poppe B, et al. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature. Eur J Haematol 2012;89: 72-80.
15. Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am JHematol 2011;86: 768-775.
16. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenstrom's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 2009: 9: 36-38.
17. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011: 470: 115-119.
18. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003: 30: 116-120.
19. Stone MJ. Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11: 157-159.
20. Tedeschi A, Barate C, Minola E, et al. Cryoglobulinemia. Blood Rev 2007;21: 183-200.
21. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2012;(5): CD002827.
22. Gertz MA, Buadi FK, Hayman SR. IgM amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk 2011;11: 146-148.
23. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108: 2520-2530.
24. Kastritis E, Kyrtsonis MC, Hatjiharissi E, et al. No signif cant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years. Am J Hematol 2011;86: 479-483.
25. Ricci F, Tedeschi A, Vismara E, et al. The impact of advanced age according to IPSSWM cut-of on the outcome of symptomatic and asymptomatic Waldenstrom's macroglobulinemia at diagnosis. Clin Lymphoma Myeloma Leuk 2011;11: 124-126.
26. Merchionne F, Procaccio P, Dammacco F. Waldenstrom's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. Crit Rev Oncol Hematol 2011: 80: 87-99.
27. Kastritis E, Zervas K, Repoussis P, et al. Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 2009: 9: 50-52.
28. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the T ird International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6: 380-383.
29. Del Giudice I, Matutes E, Osuji N, et al. Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Haematologica 2005: 90: 268-270.
30. Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009: 113: 793-796.
31. Gertz MA, Abonour R, Hefner LT, et al. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009: 147: 677-680.
32. Izzedine H, Bourry E, Amrouche L, et al. Immunoglobulin M "fare "after rituximab-associated acute tubular necrosis in Waldenstrom's macroglobulinemia. Int J Hematol 2009;89: 218-222.
33. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M "flare "after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004: 101: 2593-2598.
34. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15: 1481-1483.
35. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009: 113: 4163-4170.
36. Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 2010: 34: 1340-1343.
37. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108: 737-742.
38. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000;18: 214-226.
39. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11: 1553-1558.
40. Petrucci MT, Avvisati G, Tribalto M, et al. Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989;226: 443-447.
41. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45: 2047-2055.
42. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25: 3344-3349.
43. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113: 3673-3678.
44. Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010;28: 2233-2238.
45. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an Effective but myelosuppressive regimen to be oferedtopatientswith advanced disease. Cancer 2012;118: 434-443.
46. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008: 112: 4452-4457.
47. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15: 355-360.
48. Nobile-Orazio E. IgM paraproteinaemic neuropathies. Curr Opin Neurol 2004;17: 599-605.
49. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25: 1570-1575.
50. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28: 1422-1428.
51. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010;85: 670-674.
52. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151: 346-353.
53. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010: 28: 1408-1414.
54. Gertz MA, Reeder CB, Kyle RA, et al. Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant 2011 Aug 29. [Epub ahead of print]
55. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010: 28: 2227-2232.
56. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28: 4926-4934.
57. Rummel MJ, Niederle N, von Grunhagen U. Bendamustine plus rituximab versus CHOP plus rituximab as first-line-treatment in patients with indolent lymphomas and Waldenstr öm's macroglobulinemia. Abstract presented at The Sixth International Workshop onWaldenström's Macroglobulinemia. 6-10 October 2010. Venice, Italy.
58. Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010;85: 824-833.
59. Stone MJ, Bogen SA. Evidence-based focused review of management ofhyperviscosity syndrome. Blood 2012;119: 2205-2208.
60. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. C yclophosphamide- bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119: 4391-4394.
61. Khan ML, Reeder CB, Kumar SK, et al. A comparison ofilenalidomide/ dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012: 156: 326-333.
62. Reeder CB, Reece DE, Kukreti V, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115: 3416-3417.